Vigmed granted important patent in China
The Chinese Patent Office (State Intellectual Property Office – SIPO) has informed Vigmed that it intends to grant the Company a patent for their needle protecting solution found in the product lines CLiP® and SWiTCH.
This is Vigmed’s first Chinese patent and an important one for the Company’s market entry. The patent completes Vigmed’s scope of protection of the needle protection solution feature in CLiP® and SWiTCH in all significant markets.
Vigmed has filed, nationally and internationally, more than 90 patents and patent applications based on a number of innovation platforms. The company owns all its patents and patent applications without any restrictions. The basic patents all have a maximum validity period.
For further information contact:
CEO Henrik Olsen, +46 763-497 364
R&D Director Fredrik Thörne, +46 735-141 035
This information is information that Vigmed Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2:00 p.m. CET on January 16, 2017.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor.Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor